The discovery of selective and potent inhibitors of DYRK1A is an emerging field of investigation, as decades of research on neurodegenerative diseases, especially Alzheimer’s Disease, have recognized DYRK1A as a novel drug target for therapeutic intervention. This evidence concerns the gene DYRK1A and early-onset autosomal dominant Alzheimer disease.